CYCC

Cyclacel Pharmaceuticals Inc.

This asset is no longer available for investment.

View all assets

Price

return (12m)

0.00%

p/e

-2.47

p/bv

3.92

DIVIDEND YIELD

505.62%

CYCC price

Cyclacel Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment CYCC

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals CYCC

Valuation

P/E

-2.47

Sector -4.03

Industry -4.03

P/BV

3.92

Sector 2.05

Industry 2.05

P/Revenue (PSR)

Sector -4.26

Industry -4.26

EV/EBITDA

-7.55

Sector -238.32

Industry -238.32

EV/EBIT

-7.55

Sector -670.55

Industry -670.55

P/EBITDA

-1.49

Sector -4.23

Industry -4.23

P/EBIT

-1.49

Sector -4.29

Industry -4.29

P/Total Assets

3.24

Sector 1.45

Industry 1.45

P/Ativo Circ. Liq.

3.94

Sector -11.51

Industry -11.51

P/Cap.Giro

3.93

Sector -11.45

Industry -11.45

EPS

-2.89

Sector -2.20

Industry -2.20

BVPS

1.82

Sector 1.95

Industry 1.95

Efficiency

Gross Margin

0.00%

Sector 36.28%

Industry 36.28%

EBITDA Margin

Sector -16,822.56%

Industry -16,822.56%

EBIT Margin

Sector -4,238,732.42%

Industry -4,238,732.42%

Operating Margin

0.00%

Sector -38.78%

Industry -38.78%

Net Profit Margins

0.00%

Sector -39.92%

Industry -39.92%

Giro Ativos

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-158.95%

Sector -65.93%

Industry -65.93%

ROA

-131.14%

Sector -66.10%

Industry -66.10%

ROIC

-11,346.24%

Sector -2,918.81%

Industry -2,918.81%

Dividends

Dividend yield

505.62%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

5.77

Sector 2.91

Industry 2.91

Dívida Líquida/EBITDA

3.24

Sector -13,526,126.12

Industry -13,526,126.12

Dívida Líquida/EBIT

3.24

Sector -3.66

Industry -3.66

Dívida Líquida/Patrimônio

-1.18

Sector -1.10

Industry -1.10

Dívida Bruta/Patrimônio

0.00

Sector -0.10

Industry -0.10

Equity/Assets

0.83

Sector 0.42

Industry 0.42

Liabilities/Assets

0.18

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-22.40%

Sector -

Industry -

Fundamentals CYCC

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
CYCC	-2.47	3.92	-158.95%	505.62%	$14.24 M	0.00%
JNJ	30.06	7.44	24.76%	1.99%	$632.34 B	21.48%
PFE	18.39	1.52	8.29%	7.11%	$137.74 B	11.83%
ABBV	126.05	-69.30	-54.98%	2.60%	$458.19 B	5.79%
NVO	11.48	6.93	60.40%	3.79%	$217.68 B	37.15%
MRK	36.33	7.07	19.45%	2.56%	$324.61 B	13.59%
AZN	25.14	5.51	21.93%	1.90%	$261.15 B	17.19%
GILD	17.54	6.90	39.33%	2.47%	$161.64 B	30.99%
BMY	17.28	6.25	36.19%	4.05%	$125.69 B	15.01%
ZTS	11.99	9.80	81.75%	2.74%	$31.69 B	27.79%
REGN	15.66	2.20	14.08%	0.55%	$69.27 B	29.65%
HALO	27.62	43.86	158.82%	0.00%	$9.63 B	23.13%
AMGN	26.05	22.11	84.87%	2.60%	$203.18 B	20.96%
MCK	21.59	-123.30	-570.98%	0.39%	$102.83 B	1.18%
VRTX	28.04	6.28	22.41%	0.00%	$121.66 B	35.51%
CAH	34.58	-20.13	-58.20%	0.89%	$53.78 B	0.62%
HRMY	14.10	2.26	16.00%	0.00%	$2.05 B	16.20%
BIIB	21.68	1.59	7.36%	0.00%	$29.75 B	13.81%
MEDP	34.42	38.99	113.29%	0.00%	$16.92 B	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CYCC Historical Dividends

current DY: 505.62%

5-year average DY: 101.12%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	04/28/2025	05/01/2025	0.15000000
Dividends	07/15/2016	08/01/2016	0.007500

ABOUT Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

United States

29 years

Founded: 1997

2006

Time since IPO - 20 years

12

Employees

Cyclacel Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $14.24 million, with shareholders equity totaling $3.63 million.

The company employs approximately 12 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Cyclacel Pharmaceuticals Inc. reported $- in revenue, generating net income of $-5.77 million.

Key financial metrics include a P/E ratio of -2.47, a price-to-book (P/B) ratio of 3.92, and a trailing twelve-month dividend yield of 505.62%.

The company trades under the ticker CYCC.

Market cap

$14.24 million

Net worth

$3.63 million

$3,630,000.00

Assets

$4.40 million

$4,400,000.00

Total Shares Outstanding

2.00 million

2,000,000

Average Daily Trading Volume

$2.26 million

$2,261,865.64

Sector

Health Care

Industry

Biotechnology

CYCC

CYCC revenue and profits

Financial Results CYCC

DRAG THE FRAME TO SEE MORE DATA

CYCC cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$855.08 20,75% (12M)

P/E

21.59

0.39%

ROE

-570.98%

P/BV

-123.30

CAH - Cardinal Health

$230.27 48,08% (12M)

P/E

34.58

0.89%

ROE

-58.20%

P/BV

-20.13

JNJ - Johnson & Johnson

$267.58 63,82% (12M)

P/E

30.06

1.99%

ROE

24.76%

P/BV

7.44

MRK - Merck & Co.

$131.89 60,86% (12M)

P/E

36.33

2.56%

ROE

19.45%

P/BV

7.07

AZN - AstraZeneca

$170.63 20,86% (12M)

P/E

25.14

1.90%

ROE

21.93%

P/BV

5.51

ABBV - AbbVie

$260.03 42,23% (12M)

P/E

126.05

2.60%

ROE

-54.98%

P/BV

-69.30

NVO - Novo Nordisk

$49.48 --24,82% (12M)

P/E

11.48

3.79%

ROE

60.40%

P/BV

6.93

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$855.08 20,75% (12 M)

P/L

21.59

0.39%

ROE

-570.98%

P/VP

-123.30

CAH - Cardinal Health

$230.27 48,08% (12 M)

P/L

34.58

0.89%

ROE

-58.20%

P/VP

-20.13

JNJ - Johnson & Johnson

$267.58 63,82% (12 M)

P/L

30.06

1.99%

ROE

24.76%

P/VP

7.44

MRK - Merck & Co.

$131.89 60,86% (12 M)

P/L

36.33

2.56%

ROE

19.45%

P/VP

7.07

AZN - AstraZeneca

$170.63 20,86% (12 M)

P/L

25.14

1.90%

ROE

21.93%

P/VP

5.51

ABBV - AbbVie

$260.03 42,23% (12 M)

P/L

126.05

2.60%

ROE

-54.98%

P/VP

-69.30

NVO - Novo Nordisk

$49.48 --24,82% (12 M)

P/L

11.48

3.79%

ROE

60.40%

P/VP

6.93

Frequently Asked Questions

What is the price of Cyclacel Pharmaceuticals (CYCC) today?

A cotação de Cyclacel Pharmaceuticals (CYCC) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Cyclacel Pharmaceuticals (CYCC) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Cyclacel Pharmaceuticals (CYCC) e dados de ações do Ibovespa e mercados internacionais.

Quando Cyclacel Pharmaceuticals (CYCC) paga dividendos?

Cyclacel Pharmaceuticals (CYCC) não distribuiu dividendos no último ano.

Is Cyclacel Pharmaceuticals (CYCC) a good investment?

Atualmente, Cyclacel Pharmaceuticals (CYCC) está cotada a US$ 0.00, com um P/L de -2.47, representando um desvio de -19,268% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 505.62%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Cyclacel Pharmaceuticals (CYCC) stock?

Investir em ações de Cyclacel Pharmaceuticals (CYCC) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Cyclacel Pharmaceuticals (CYCC) yield today?

A rentabilidade de Cyclacel Pharmaceuticals (CYCC) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 505.62%.

Se você quisesse comprar 100 ações de Cyclacel Pharmaceuticals (CYCC) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CYCC

Cyclacel Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CYCC

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

current DY: 505.62%

5-year average DY: 101.12%

type

Ex - Dividend Date

payment date

value

ABOUT Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc.

United States

29 years

2006

12

PROFIT X PRICE CYCC

Financial Results CYCC

CYCC cash flow

Asset, Revenue and Profit Growth - CYCC

CYCC balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

Frequently Asked Questions